Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Ott Website

David E. Ott, Ph.D.

Selected Publications
1)  Coren LV, Shatzer T, Ott DE.
CD45 immunoaffinity depletion of vesicles from Jurkat T cells demonstrates that.
Retrovirology. 5: 64, 2008. [Journal]
2)  Minang JT, Barsov EV, Yuan F, Trivett MT, Piatak M, Lifson JD, Ott DE, Ohlen C.
Efficient inhibition of SIV replication in rhesus CD4+ T-cell clones by autologous immortalized SIV-specific CD8+ T-cell clones.
Virology. 372: 430-41, 2008. [Journal]
3)  Ott DE.
Laparoscopy and adhesion formation, adhesions and laparoscopy.
Semin. Reprod. Med. 26: 322-30, 2008. [Journal]
4)  Gousset K, Ablan SD, Coren LV, Ono A, Soheilian F, Nagashima K, Ott DE, Freed EO.
Real-time visualization of HIV-1 GAG trafficking in infected macrophages.
PLoS Pathog. 4: e1000015, 2008. [Journal]
5)  Chan R, Uchil PD, Jin J, Shui G, Ott DE, Mothes W, Wenk MR.
RETROVIRUSES HIV AND MLV ARE ENRICHED IN PHOSPHOINOSITIDES.
J. Virol. 2008. [Journal]
6)  Minang JT, Trivett MT, Coren LV, Barsov EV, Piatak M, Chertov O, Chertova E, Ott DE, Ohlen C.
The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness.
Virology. 375: 307-14, 2008. [Journal]
7)  Thomas JA, Ott DE, Gorelick RJ.
Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions.
J. Virol. 81: 4367-70, 2007. [Journal]
8)  Coren LV, Thomas JA, Chertova E, Sowder RC, Gagliardi TD, Gorelick RJ, Ott DE.
Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1.
J. Virol. 81: 10047-54, 2007. [Journal]
9)  Melar M, Ott DE, Hope TJ.
Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux.
J. Virol. 81: 1773-85, 2007. [Journal]
10)  Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK.
Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
Virology. 360: 247-56, 2007. [Journal]
11)  Andersen H, Barsov EV, Trivett MT, Trubey CM, Giavedoni LD, Lifson JD, Ott DE, Ohlén C.
Transduction with human telomerase reverse transcriptase immortalizes a rhesus macaque CD8+ T cell clone with maintenance of surface marker phenotype and function.
AIDS Res. Hum. Retroviruses. 23: 456-65, 2007. [Journal]
12)  Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Sowder RC, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE.
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.
J. Virol. 80: 9039-52, 2006. [Journal]
13)  Ott DE.
Cellular proteins detected in HIV-1.
Rev. Med. Virol. 18: 159-75, , ,. [Journal]
14)  Barsov EV, Andersen H, Coalter VJ, Carrington M, Lifson JD, Ott DE.
Capture of antigen-specific T lymphocytes from human blood by selective immortalization to establish long-term T-cell lines maintaining primary cell characteristics.
Immunol. Lett. 105: 26-37, 2006. [Journal]
15)  Rudner L, Nydegger S, Coren LV, Nagashima K, Thali M, Ott DE.
Dynamic fluorescent imaging of human immunodeficiency virus type 1 gag in live cells by biarsenical labeling.
J. Virol. 79: 4055-65, 2005. [Journal]
16)  Morcock DR, Thomas JA, Gagliardi TD, Gorelick RJ, Roser JD, Chertova EN, Bess JW, Ott DE, Sattentau QJ, Frank I, Pope M, Lifson JD, Henderson LE, Crise BJ.
Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.
J. Virol. 79: 1533-42, 2005. [Journal]
17)  Ott DE, Coren LV, Gagliardi TD, Nagashima K.
Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1.
J. Virol. 79: 9038-45, 2005. [Journal]
18)  Vázquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, Schubert U, Henklein P, Orenstein JM, Sporn MB, Wahl SM.
Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation.
J. Virol. 79: 4479-91, 2005. [Journal]
19)  Ott DE, Coren LV, Gagliardi TD.
Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly.
J. Virol. 79: 13839-47, 2005. [Journal]
20)  Ott DE, Coren LV, Chertova EN, Gagliardi TD, Nagashima K, Sowder RC, Poon DT, Gorelick RJ.
Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.
J Virol. 77: 5547-56, 2003. [Journal]
21)  Trubey CM, Chertova E, Coren LV, Hilburn JM, Hixson CV, Nagashima K, Lifson JD, Ott DE.
Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles.
J Virol. 77: 12699-709, 2003. [Journal]
22)  Ott DE, Coren LV, Sowder RC, Adams J, Schubert U.
Retroviruses have differing requirements for proteasome function in the budding process.
J Virol. 77: 3384-93, 2003. [Journal]
23)  Ott DE, Coren LV, Sowder RC, Adams J, Nagashima K, Schubert U.
Equine infectious anemia virus and the ubiquitin-proteasome system.
J. Virol. 76: 3038-44, 2002. [Journal]
24)  Qian SB, Ott DE, Schubert U, Bennink JR, Yewdell JW.
Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo.
J. Biol. Chem. 277: 38818-26, 2002. [Journal]
25)  Poon DT, Chertova EN, Ott DE.
Human immunodeficiency virus type 1 preferentially encapsidates genomic RNAs that encode Pr55(Gag): functional linkage between translation and RNA packaging.
Virology. 293: 368-78, 2002. [Journal]
26)  Ott DE.
Potential roles of cellular proteins in HIV-1.
Rev. Med. Virol. 12: 359-74, 2002. [Journal]
27)  Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW, Arthur LO, Ott DE, Lifson JD.
Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation.
J. Virol. 75: 6173-82, 2001. [Journal]
28)  Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC, Kim YD, Fisher RJ, Zhou XZ, Lu KP, Henderson LE.
Actin-binding cellular proteins inside human immunodeficiency virus type 1.
Virology. 266: 42-51, 2000. [Journal]
29)  Poon DT, Coren LV, Ott DE.
Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging.
J. Virol. 74: 3918-23, 2000. [Journal]
30)  Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW.
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
Proc. Natl. Acad. Sci. U.S.A. 97: 13057-62, 2000. [Journal]
31)  Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U.
Ubiquitination of HIV-1 and MuLV Gag.
Virology. 278: 111-21, 2000. [Journal]

This page was last updated on 9/23/2008.